nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.09.2009 | Focus on

Monitoring cancer therapy with PET: probably effective, but more research is needed

verfasst von: Giovanni Lucignani

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Excerpt

"About one person in six is now slain by neoplastic cells. Can nothing be done to combat these?”[1]

Peyton Rous (1879-1970)

…

http://nobelprize.org/nobel_prizes/medicine/laureates/1966/rous-bio.html.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef

Herrmann K, Krause BJ, Bundschuh RA, Dechow T, Schwaiger M. Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med. 2009;39(3):210–32.PubMedCrossRef

Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15(8):2856–63.PubMedCrossRef

Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys. 2009;73(4):1228–34.PubMed

Hamada K, Tomita Y, Inoue A, Fujimoto T, Hashimoto N, Myoui A, et al. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med. 2009;23(1):89–95.PubMedCrossRef

Byström P, Berglund A, Garske U, Jacobsson H, Sundin A, Nygren P, et al. Early prediction of response to first-line chemotherapy by sequential [¹⁸F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol. 2009;20(6):1057–61.PubMedCrossRef

Cerfolio RJ, Bryant AS, Talati AA, Eloubeidi MA, Cerfolio RM, Winokur TS. Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders. J Thorac Cardiovasc Surg. 2009 Mar;137(3):605–9. Erratum in: J Thorac Cardiovasc Surg. 2009 Jun;137(6):1581. Eloubeidi, Mohamad A [added].

Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol. 2009;19(6):1347–57.PubMedCrossRef

10.

Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer. 2009;45(2):290–9.PubMedCrossRef

11.

Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009;15(6):1891–7.PubMedCrossRef

12.

Larson SM, Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q J Nucl Med Mol Imaging. 2009;53(2):158–66.PubMed

13.

Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11(8):2785–808.PubMedCrossRef

14.

Eckelman WC, Reba RC, Kelloff GJ. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today. 2008;13(17–18):748–59.PubMedCrossRef

Titel: Monitoring cancer therapy with PET: probably effective, but more research is needed
verfasst von: Giovanni Lucignani
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1214-x

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Monitoring cancer therapy with PET: probably effective, but more research is needed

Excerpt

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2009

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients

99Mo supply—the times they are a-changing

The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy

Incidental head and neck 18F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development?

Staging primary head and neck cancers with 18F-FDG PET/CT: is intravenous contrast administration really necessary?